Reliance Life Sciences azacitidine recalled for sterility assurance
Reliance Life Sciences is recalling azacitidine for injection, 100 mg single-dose vials, manufactured for Somerset Therapeutics. The notice cites a lack of sterility assurance for 8,001 vials across 12 lots, distributed nationwide. No injuries have been reported.
From the FDA notice · Read the official notice ↗
What to do
- Set aside affected vials and do not administer them.
- Check NDC 70069-0857-01 and lots RAZM0425A through RAZM2025A (expiry June to September 2027) on vial cartons.
- The notice does not say how to get a replacement or refund; contact Somerset Therapeutics, LLC.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For Subcutaneous and Intravenous Use, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873 NDC: 70069-0857-01
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
This recall covers 4 products — see all of them.
Details
- Units affected
- 8,001 vials
- Illnesses reported
- None reported
- Manufactured in
- Ttc Area Of Midc, R - 282 Dhirubhai Ambani Life Sciences Centre; Thane Belapur Road, Navi Mumbai, N/A, India
- Classification
- Class II
- Recall number
- D-0674-2026
In the FDA's words
- Description
- Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For Subcutaneous and Intravenous Use, Rx only, Manufactured for: Somerset Therapeutics, LLC., Somerset, NJ 08873 NDC: 70069-0857-01 Lack of Sterility Assurance Lot, expiry: RAZM0425A Jun 30, 2027; RAZM0525A Jun 30, 2027; RAZM0725A Jun 30, 2027; RAZM0825A Jun 30, 2027; RAZM0925A Jul 31, 2027; RAZM1125A Jul 31, 2027; RAZM1225A Jul 31, 2027; RAZM1425A Jul 31, 2027; RAZM1525A Jul 31, 2027; RAZM1625A Aug 31, 2027; RAZM1725A Aug 31, 2027; RAZM2025A Sep 30, 2027 Distribution: Nationwide in the USA Affected quantity: 8,001 vials
- Hazard
- Lack of Sterility Assurance
4 products in this recall
Somerset Therapeutics cancer drug vials recalled for lack of sterility
Reliance Life Sciences is recalling four injectable cancer drugs made for Somerset Therapeutics: Pemetrexed for Injection 100 mg and 500 mg vials, Bortezomib for Injection 3.5 mg vials, and Azacitidine for Injection 100 mg vials. The recall covers about 36,000 vials nationwide because of a lack of sterility assurance. No injuries have been reported.
The agency lists each product separately. Check every one you might have.
- Pemetrexed for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For intravenous use only, Rx only, Manufactured for: Somerset Therapeutics, LLC.,…D-0671-2026 · 12,000 vials
- Pemetrexed for Injection 500mg/Vial, 1 50 mL Single-Dose Vial per carton, For intravenous use only, Rx only, Manufactured for: Somerset Therapeutics, LLC.,…D-0672-2026 · 5,020 vials
- Bortezomib for Injection 3.5mg/Vial, 10 mL per Single-Dose Vial, For Intravenous or Subcutaneous Use, Manufactured for: Somerset Therapeutics, LLC., Somerset…D-0673-2026 · 11,400 vials
- Azacitidine for Injection 100mg/Vial, 1 10 mL Single-Dose Vial per carton, For Subcutaneous and Intravenous Use, Rx only, Manufactured for: Somerset Therap… (this page)D-0674-2026 · 8,001 vials